Industry News
Motif Neurotech's DOT wins FDA IDE for first clinical trial in treatment-resistant depression
The FDA has approved Motif Neurotech's investigational device exemption to begin a first-in-patient clinical trial of DOT, a millimeter-scale epidurally implanted wirelessly powered brain stimulator that targets the prefrontal cortex. The Rice University spinout, backed by former Neuralink president Max Hodak among others, becomes one of the first companies to attempt an implantable depression therapy at the size and patient-acceptance profile that has eluded every prior DBS-for-depression programme.